29 results on '"Tretarre B"'
Search Results
2. International incidence of childhood cancer, 2001-10 a population-based registry study
- Author
-
Steliarova Foucher Eva, Colombet, Murielle, Ries Lynn, A. G., Moreno, Florencia, Dolya, Anastasia, Bray, Freddie, Hesseling, Peter, Shin, Hee Young Stiller, Iicc, 3 contributors, Bouzbid, S, Hamdi Cherif, M, Hablas, A, Chirpaz, E, Buziba, N, Chesumbai, Gc, Manraj, Ss, Reynders, D, Wabinga, Hr, Chokunonga, E, Moreno, F, Lima, Ca, Asturian Laporte, C, de Oliveira JC, de Aquino JP, Gallagher, Sv, Uribe, Cj, Bravo, Le, Yepez Chamorro MC, Torres Alvarado, G, Galán Alvarez YH, Martinez Reyes FC, Castillo Calvas JC, Mendoza Alava, M, Cueva Ayala, P, Hanchard, B, Fajardo Gutiérrez, A, Zavala Zegarra DE, Barrios, E, Nikiforuk, C, Woods, R, Turner, D, Macintyre, M, Corriveau, A, Navaneelan, T, Bertrand, C, Stuart Panko, H, Wilson, Rj, Kosary, C, Shen, X, Brockhouse, J, Yee, Ga, Mitchell, Tc, Snipes, K, West, D, Rao, C, Bolick, S, Rycroft, Rk, Mueller, L, Zheng, Y, Dosch, K, Brown, H, Vargas, A, Levin, Gm, Bayakly, R, Johnson, C, Shen, T, Ruppert, L, Lynch, Cf, Lai, Sm, Tucker, Tc, Wu, Xc, Schwenn, M, Stern, K, Gershman, S, Copeland, G, Bushhouse, S, Rogers, Db, Jackson Thompson, J, Lemons, D, Frederick, S, Harris, Ja, Riddle, B, Stroup, A, Wiggins, C, Schymura, Mj, Giljahn, Lk, Sheikh, A, Schubert, S, Aldinger, W, Fulton, Jp, Whiteside, M, Nogueira, L, Sweeney, C, Johnson, A, Martin, J, Farley, S, Harrelson, D, Malicki, R, Espinoza, Jr, Hernandez, By, Abulfateh, N, Wang, N, Ngan, R, Lingegowda, Kb, Swaminathan, R, Koyande, Ss, Silverman, B, Ozasa, K, Kanemura, S, Soda, M, Miyashiro, I, Shibata, A, Nimri, O, Won, Yj, Kim, Ch, Hong, Ns, Nam, Hs, Kweon, S, Kim, Wc, Huh, Js, Jung, Kw, Yoo, Ci, Elbasmy, A, Laudico, Av, Lumague, Mr, Almutlag, H, Buasom, R, Srisukho, S, Tanabodee, J, Wiangnon, S, Pongnikorn, D, Sriplung, H, Dirican, O, Eser, S, Le Hoang, M, Hackl, M, Zborovskaya, A, Dimitrova, N, Valerianova, Z, Sekerija, M, Pavlou, P, Dušek, M, Mägi, M, Clavel, J, Lacour, B, Guizard, Av, Bouvier, V, Troussard, X, Woronoff, As, Tretarre, B, Colonna, M, Molinié, F, Bara, S, Velten, M, Marrer, E, Ganry, O, Grosclaude, P, Kaatsch, P, Zeissig, Sr, Holleczek, B, Katalinic, A, Jakab, Z, Birgisson, H, Walsh, Pm, Mangone, L, Merletti, Franco, Magoni, M, Ferretti, S, Serraino, D, Spagnoli, G, Fusco, M, Michiara, M, Tumino, R, Falcini, F, Sensi, F, Tisano, F, Piffer, S, Stracci, F, Tagliabue, G, Smailyte, G, Agius, D, Visser, O, Ursin, G, Didkowska, J, Trojanowski, M, Wojciechowska, U, Forjaz de Lacerda, G, Silva, Ma, Laranja Pontes, J, da Costa Miranda, A, Kaiserova, E, Primic Žakelj, M, Peris Bonet, R, Vicente Raneda ML, Almar Marqués, E, Quirós Garcia JR, Ramos Monserrat, M, Errezola Saizar, M, Alemán Herrera, A, Díaz García JM, Marcos Gragera, R, Sanchez Perez MJ, Ardanaz Aicua, E, Galceran, J, Klint, A, Kuehni, Ce, Bouchardy, C, Levi, F, Bordoni, A, Konzelmann, I, Rohrmann, S, Stiller, Ca, Gavin, At, Brewster, Dh, Phung, H, Rushton, S, Guthridge, S, Aitken, J, D'Onise, K, Venn, A, Farrugian, H, Threlfall, Tj, Laumond, S, Yen Kai Sun, L, Hendrix, J, Ballantine, K, Colombet, M, Dolya, A, Masuyer, E, Steliarova Foucher, E., IICC-3 contributors, Bouzbid, S., Hamdi-Cherif, M., Hablas, A., Chirpaz, E., Buziba, N., Chesumbai, G.C., Manraj, S.S., Reynders, D., Wabinga, H.R., Chokunonga, E., Moreno, F., Lima, C.A., Asturian Laporte, C., de Oliveira, J.C., de Aquino, J.P., Gallagher, S.V., Uribe, C.J., Bravo, L.E., Yepez Chamorro, M.C., Torres Alvarado, G., Galán Alvarez, Y.H., Martinez Reyes, F.C., Castillo Calvas, J.C., Mendoza Alava, M., Cueva Ayala, P., Hanchard, B., Fajardo-Gutiérrez, A., Zavala Zegarra, D.E., Barrios, E., Nikiforuk, C., Woods, R., Turner, D., MacIntyre, M., Corriveau, A., Navaneelan, T., Bertrand, C., Stuart-Panko, H., Wilson, R.J., Kosary, C., Shen, X., Brockhouse, J., Yee, G.A., Mitchell, T.C., Snipes, K., West, D., Rao, C., Bolick, S., Rycroft, R.K., Mueller, L., Zheng, Y., Dosch, K., Brown, H., Vargas, A., Levin, G.M., Bayakly, R., Johnson, C., Shen, T., Ruppert, L., Lynch, C.F., Lai, S.M., Tucker, T.C., Wu, X.C., Schwenn, M., Stern, K., Gershman, S., Copeland, G., Bushhouse, S., Rogers, D.B., Jackson Thompson, J., Lemons, D., Frederick, S., Harris, J.A., Riddle, B., Stroup, A., Wiggins, C., Schymura, M.J., Giljahn, L.K., Sheikh, A., Schubert, S., Aldinger, W., Fulton, J.P., Whiteside, M., Nogueira, L., Sweeney, C., Johnson, A., Martin, J., Farley, S., Harrelson, D., Malicki, R., Espinoza, J.R., Hernandez, B.Y., Abulfateh, N., Wang, N., Ngan, R., Lingegowda, K.B., Swaminathan, R., Koyande, S.S., Silverman, B., Ozasa, K., Kanemura, S., Soda, M., Miyashiro, I., Shibata, A., Nimri, O., Won, Y.J., Kim, C.H., Hong, N.S., Nam, H.S., Kweon, S., Kim, W.C., Huh, J.S., Jung, K.W., Yoo, C.I., Elbasmy, A., Laudico, A.V., Lumague, M.R., AlMutlag, H., Buasom, R., Srisukho, S., Tanabodee, J., Wiangnon, S., Pongnikorn, D., Sriplung, H., Dirican, O., Eser, S., Le Hoang, M., Hackl, M., Zborovskaya, A., Dimitrova, N., Valerianova, Z., Sekerija, M., Pavlou, P., Dušek, M., Mägi, M., Clavel, J., Lacour, B., Guizard, A.V., Bouvier, V., Troussard, X., Woronoff, A.S., Tretarre, B., Colonna, M., Molinié, F., Bara, S., Velten, M., Marrer, E., Ganry, O., Grosclaude, P., Kaatsch, P., Zeissig, S.R., Holleczek, B., Katalinic, A., Jakab, Z., Birgisson, H., Walsh, P.M., Mangone, L., Merletti, F., Magoni, M., Ferretti, S., Serraino, D., Spagnoli, G., Fusco, M., Michiara, M., Tumino, R., Falcini, F., Sensi, F., Tisano, F., Piffer, S., Stracci, F., Tagliabue, G., Smailyte, G., Agius, D., Visser, O., Ursin, G., Didkowska, J., Trojanowski, M., Wojciechowska, U., Forjaz de Lacerda, G., Silva, M.A., Laranja Pontes, J., da Costa Miranda, A., Kaiserova, E., Primic Žakelj, M., Peris-Bonet, R., Vicente Raneda, M.L., Almar Marqués, E., Quirós Garcia, J.R., Ramos Monserrat, M., Errezola Saizar, M., Alemán Herrera, A., Díaz García, J.M., Marcos-Gragera, R., Sanchez-Perez, M.J., Ardanaz Aicua, E., Galceran, J., Klint, A., Kuehni, C.E., Bouchardy, C., Levi, F., Bordoni, A., Konzelmann, I., Rohrmann, S., Stiller, C.A., Gavin, A.T., Brewster, D.H., Phung, H., Rushton, S., Guthridge, S., Aitken, J., D'Onise, K., Venn, A., Farrugian, H., Threlfall, T.J., Laumond, S., Yen Kai Sun, L., Hendrix, J., Ballantine, K., Colombet, M., Dolya, A., Masuyer, E., Steliarova-Foucher, E., University of Zurich, and Steliarova-Foucher, Eva
- Subjects
0301 basic medicine ,Male ,Pediatrics ,cancer incidence ,sistema de registros ,humanos ,Ethnic group ,adolescente ,population-based registry study ,North America/epidemiology ,0302 clinical medicine ,Neoplasms ,Medicine ,Registries ,Young adult ,Child ,Cancer in children -- Mortality ,Cause of death ,neoplasias ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,South America/epidemiology ,Articles ,Càncer en els infants -- Mortalitat ,incidence, cancer registry, childhood cancer ,3. Good health ,adulto joven ,Caribbean Region/epidemiology ,Oncology ,Oceania/epidemiology ,030220 oncology & carcinogenesis ,Child, Preschool ,Oncology, childhood, cancer, population-based registry study, cancer incidence ,2730 Oncology ,Female ,medicine.medical_specialty ,Oceanía ,Adolescent ,Oceania ,Population ,Socio-culturale ,610 Medicine & health ,incidencia ,Europe/epidemiology ,03 medical and health sciences ,Young Adult ,Age Distribution ,distribución por edades ,SDG 3 - Good Health and Well-being ,cancer ,Humans ,education ,childhood ,lactante ,Asia/epidemiology ,business.industry ,Cancer ,Infant ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) ,medicine.disease ,Cancer registry ,030104 developmental biology ,Africa/epidemiology ,business ,Neoplasms/epidemiology ,International Classification of Diseases for Oncology ,Demography - Abstract
Background Cancer is a major cause of death in children worldwide, and the recorded incidence tends to increase with time. Internationally comparable data on childhood cancer incidence in the past two decades are scarce. This study aimed to provide internationally comparable local data on the incidence of childhood cancer to promote research of causes and implementation of childhood cancer control. Methods This population-based registry study, devised by the International Agency for Research on Cancer in collaboration with the International Association of Cancer Registries, collected data on all malignancies and nonmalignant neoplasms of the CNS diagnosed before age 20 years in populations covered by high-quality cancer registries with complete data for 2001-10. Incidence rates per million person-years for the 0-14 years and 0-19 years age groups were age-adjusted using the world standard population to provide age-standardised incidence rates (WSRs), using the age-specific incidence rates (ASR) for individual age groups (0-4 years, 5-9 years, 10-14 years, and 15-19 years). All rates were reported for 19 geographical areas or ethnicities by sex, age group, and cancer type. The regional WSRs for children aged 0-14 years were compared with comparable data obtained in the 1980s. Findings Of 532 invited cancer registries, 153 registries from 62 countries, departments, and territories met quality standards, and contributed data for the entire decade of 2001-10. 385 509 incident cases in children aged 0-19 years occurring in 2.64 billion person-years were included. The overall WSR was 140.6 per million person-years in children aged 0-14 years (based on 284 649 cases), and the most common cancers were leukaemia (WSR 46.4), followed by CNS tumours (WSR 28.2), and lymphomas (WSR 15.2). In children aged 15-19 years (based on 100 860 cases), the ASR was 185.3 per million person-years, the most common being lymphomas (ASR 41.8) and the group of epithelial tumours and melanoma (ASR 39.5). Incidence varied considerably between and within the described regions, and by cancer type, sex, age, and racial and ethnic group. Since the 1980s, the global WSR of registered cancers in children aged 0-14 years has increased from 124.0 (95% CI 123.3-124.7) to 140.6 (140.1-141.1) per million person-years. Interpretation This unique global source of childhood cancer incidence will be used for aetiological research and to inform public health policy, potentially contributing towards attaining several targets of the Sustainable Development Goals. The observed geographical, racial and ethnic, age, sex, and temporal variations require constant monitoring and research., International Agency for Research on Cancer and the Union for International Cancer Control.
- Published
- 2017
3. The advantage of women in cancer survival: An analysis of EUROCARE-4 data
- Author
-
Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health
- Subjects
Oncology ,Male ,Pathology ,Cancer Research ,cancer survival - women ,MESH : Age Distribution ,MESH : Aged ,MESH: Risk Assessment ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,Residence Characteristics ,Neoplasms ,80 and over ,Gender differences ,Sex hormones ,MESH: Neoplasms ,MESH : Female ,MESH: Residence Characteristics ,Young adult ,Age of Onset ,MESH : Risk Assessment ,MESH : Sex Distribution ,MESH: Diagnosis-Related Groups ,MESH: Aged ,Aged, 80 and over ,0303 health sciences ,education.field_of_study ,MESH: Middle Aged ,Relative survival ,Thyroid ,MESH: Sex Distribution ,Middle Aged ,MESH : Adult ,3. Good health ,MESH : Age of Onset ,Europe ,MESH : Diagnosis-Related Groups ,medicine.anatomical_structure ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,MESH : Residence Characteristics ,Female ,EUROCARE ,Adult ,medicine.medical_specialty ,Adolescent ,MESH: Age of Onset ,MESH : Male ,MESH : Sex Factors ,Population ,MESH : Europe ,MESH : Young Adult ,Rectum ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Risk Assessment ,03 medical and health sciences ,Young Adult ,Age Distribution ,Sex Factors ,MESH: Sex Factors ,SDG 3 - Good Health and Well-being ,Internal medicine ,MESH : Adolescent ,medicine ,Humans ,MESH : Middle Aged ,Sex Distribution ,education ,MESH : Aged, 80 and over ,MESH: Age Distribution ,Survival analysis ,Diagnosis-Related Groups ,030304 developmental biology ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,Cancer survival ,Survival Analysis ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,MESH: Europe ,Age of onset ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.
- Published
- 2009
4. Breast carcinoma survival in Europe and the United States
- Author
-
Sant, M., Allemani, C., Berrino, F., Coleman, M. P., Aareleid, T., Chaplain, G., Coebergh, J. W., Colonna, M., Crosignani, P., Danzon, A., Federico, Massimo, Gafà, L., Grosclaude, P., Hédelin, G., Macè Lesech, J., Martinez Garcia, C., Møller, H., Paci, E., Raverdy, N., Tretarre, B., Williams, E. M. I., Kupp, A., Exbrayat, C., Mercier, M., Artioli, E., Barchielli, A., Gatta, G., Speciale, D., Ruzza, M. R., Frassoldi, E., Capocaccia, R., Verdecchia, A., Tumino, R., La Rosa, M., Voogd, A., Bell, J., and Youngson, J.
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,Axillary lymph nodes ,business.industry ,Obstetrics ,medicine.medical_treatment ,Population ,Absolute risk reduction ,Cancer ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Carcinoma ,Medicine ,Lymphadenectomy ,Breast carcinoma, Cancer registries, Europe, Stage, Survival, U.S ,Breast carcinoma ,business ,education ,Survival rate - Abstract
BACKGROUND Breast carcinoma survival rates were found to be higher in the U.S. than in Europe. METHODS Multiple regression analysis of breast carcinoma survival rates among women diagnosed between 1990 and 1992 was performed using clinical data from population-based case series from the Surveillance, Epidemiogy, and End Results (SEER) program (13,172 women) and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS Early-stage tumors (T1N0M0) were more frequent in the SEER data (41% of cases) than in the EUROCARE data (29%). In the SEER data, early tumors were more frequent in women age ≥ 65 years (43%) than in younger women (38%), whereas the reverse was true in the European data (25% vs. 31%). In both case series, > 90% of women underwent surgery and 81–82% underwent lymphadenectomy, but the number of axillary lymph nodes evaluated was higher in the SEER data than in the EUROCARE data. The 5-year survival rate was higher in the U.S. case series (89%) than in the European series (79%). This differential was observed for each stage category evaluated: early (T1N0M0), large lymph node-negative (T2–3N0M0), lymph node-positive (T1–3N+M0), locally advanced (T4M0), and metastatic (M1) tumors. The overall relative excess risk (RER) of death was significantly higher (RER, 1.37; 95% confidence interval [95% CI], 1.25–1.50) among European women compared with U.S. women (referent group). Adjustment for stage, age, surgery, and the number of lymph nodes evaluated explained most of the excess risk (RER, 1.07; 95% CI, 0.98–1.17). CONCLUSIONS Transatlantic differences in the 5-year survival rates for women diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly to differences in stage of disease. Resources should be invested to achieve earlier diagnosis of breast carcinoma in Europe, especially for elderly women. Cancer 2004;100:715–22. © 2003 American Cancer Society.
- Published
- 2003
5. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary
- Author
-
Sant, M., Aareleid, T., Berrino, F., Bielska Lasota, M., Carli, P. M., Faivre, J., Grosclaude, P., Hédelin, G., Matsuda, T., Møller, H., Möller, T., Verdecchia, A., Capocaccia, R., Gatta, G., Micheli, A., Santaquilani, M., Roazzi, P., Lisi, D., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Hakulinen, T., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Chaplain, G., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Ciccolallo, L., Taussig, E., Carrani, E., De Angelis, R., Hartley, S., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, Aw, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmak, F., Andersen, A., Rachtan, J., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Lutz, J. M., Usel, M., Coebergr, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.
- Subjects
Male ,Urologic Neoplasms ,medicine.medical_specialty ,Lung Neoplasms ,Skin Neoplasms ,Genital Neoplasms, Female ,Breast Neoplasms ,Digestive System Neoplasms ,Sex Factors ,Case mix index ,Testicular Neoplasms ,Neoplasms ,Internal medicine ,Epidemiology ,medicine ,Humans ,Registries ,Thyroid Neoplasms ,cancer survival ,Survival rate ,Testicular cancer ,Survival analysis ,Brain Neoplasms ,business.industry ,Prostatic Neoplasms ,Cancer ,Hematology ,medicine.disease ,Survival Analysis ,Age-standardised relative survival, Cancer survival, Europe, International comparison, Population-based cancer registries ,Lymphoma ,Surgery ,Europe ,Survival Rate ,Oncology ,Head and Neck Neoplasms ,Hematologic Neoplasms ,Female ,business - Abstract
EUROCARE-3 analysed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries. The results are reported in tables, one per cancer site, coded according to the International Classification of Diseases (ICD)-9 classification. The main findings of the tables are summarised and commented on in this article. For most solid cancers, wide differences in survival between different European populations were found, as also reported by EUROCARE-1 and EUROCARE-2, despite a remarkable (10%) overall increase in cancer survival from 1985 to 1994. Survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain). Survival was particularly low in eastern Europe, low in Denmark and the UK, and fairly low in Portugal and Malta. The mix of tumour stage at diagnosis explains much of the survival differences for cancers of the digestive tract, female reproductive system, breast, thyroid, and also skin melanoma. For tumours of the urinary tract and prostate, the differences were explained mainly by differences in diagnostic criteria and procedures. The case mix by anatomic subsite largely explains differences in survival for head and neck cancers. For oesophagus, pancreas, liver and brain cancer, with poor prognoses, survival differences were limited. Tumours, for which highly effective treatments are available, such as testicular cancer, Hodgkin's lymphoma and some haematological malignancies, had fairly uniform survival across Europe. Survival for all tumours combined (an indicator of the overall cancer care performance of a nation's health system) was better in young than old patients, and better in women than men. The affluence of countries influenced overall cancer survival through the availability of adequate diagnostic and treatment procedures, and screening programmes.
- Published
- 2003
6. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
- Author
-
Coleman, M. P., Gatta, G., Verdecchia, A., Estève, J., Sant, M., Storm, H., Allemani, C., Ciccolallo, L., Santaquilani, M., Berrino, F., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Faivre, J., Chaplain, G., Carl, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estèv, Z, Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Baili, P., Micheli, A., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Roazzi, P., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P. Guzzinati S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Möller, T., Jundt, G. Lutz J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., Steward, J. A., Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT] ,Pathology ,medicine.medical_specialty ,population-based cancer registries ,Lung Neoplasms ,Skin Neoplasms ,Population ,Uterine Cervical Neoplasms ,Breast Neoplasms ,Disease ,Sex Factors ,Testicular Neoplasms ,Stomach Neoplasms ,Neoplasms ,Epidemiology ,Health care ,Humans ,Medicine ,Registries ,cancer survival ,Child ,education ,Survival rate ,Survival analysis ,education.field_of_study ,business.industry ,Age Factors ,international comparison ,Prostatic Neoplasms ,Cancer ,Hematology ,medicine.disease ,Survival Analysis ,Cancer survival ,Europe ,Survival Rate ,Oncology ,Colonic Neoplasms ,Female ,Observational study ,business ,Demography - Abstract
Summary International differences and trends in cancer survival withinEurope are larger than can reasonably be accounted for by arte-fact, bias or chance. The geographical patterns and trends in sur-vival are often broadly consistent with geographical differences ortrends in the type of cancer, diagnostic investigations or overallinvestment in health care, and for several major cancers, support-ing evidence is available from population-based studies of clinicalinformation. Incomplete ascertainment of cancer cases, particu-larly of long-term survivors, may contribute to some regional andinternational differences in survival, however, and more system-atic information on completeness is required. We may concludethat large international differences in survival do exist for manycancers, but we should be cautious in drawing quantitative orcausal conclusions from observational survival data.We do not yet have a fully satisfactory interpretation of thesedifferences, but we have few alternatives to this type of study if weare to understand the determinants of improved outcome for allcancer patients, and to enable better planning of their health care.The EUROCARE Working Group has developed several strategiesto disentangle the various possible explanations [73]. These includefurther development of high-resolution studies to examine theimpact on survival differences of disease stage, staging techniquesand treatment; and further development of mathematical modelsof cure. Extension of systematic international survival compari-sons to other regions of the world, such as Australia, Canada, Japanand the USA, is also in progress (the CONCORD study) [22].Oncologists and epidemiologists may provide insight into thegeographic differences and trends in survival reported by thisstudy, and may suggest further lines of enquiry. Do we need morerefined studies of survival to monitor progress against cancer andto plan future cancer care? Will such analyses help us quantify theeffect of new treatments arising from recent progress in the basicsciences and genomics on population cancer survival rates? Sub-stantial human and financial resources are required to improve theoutcome of cancer treatment. Will future investments in cancerservices include matching investment to monitor their impact onsurvival and mortality?Earlier diagnosis and prompt, universal access to optimal treat-ment would be expected to reduce international differences incancer survival in Europe. To achieve this, oncologists and healthcare planners will need better information on the comparativeperformance of their health systems. Population-based cancer reg-istries provide some of the information for such comparisons, buttheir traditional output may no longer be sufficient to evaluate theeffectiveness of health systems, and especially to explain geo-graphical differences in survival. In some countries, their role isalso under threat. Confidentiality constraints recently inhibitedthe collection of cancer registration data in the UK [90], and thelinkage of cancer registrations and deaths is currently illegal inEstonia [91]. Both activities are essential for internationally com-parable survival rates. Legal protection for cancer registrationacross Europe will be required.The mission of cancer registries should be reconsidered, and thepriority shifted from classical descriptive epidemiology and geo-graphical pathology toward more analytical monitoring ofprogress against cancer, including the probability of survival andcure, the burden of cancer prevalence, and the late effects oftherapy. Several European studies of this type have been reportedrecently [3, 36, 9294] and others are in progress. Many cancer–registries are developing closer relationships with cancer clini-cians and general practitioners, and some now systematicallycollect detailed clinical information that was collected eitherirregularly or not at all in the past. These developments willimprove the power of population-based cancer data to explain dif-ferences in cancer survival, and should enhance their relevance toclinical practice.European average survival rates are useful for comparativepurposes, but they should not become the goal for cancer controlprogrammes: the benchmark should always be the highest achiev-able survival rates.The aim of exploring geographic differences in cancer survivalis not to establish international league tables or to excite nationalrivalries, but to estimate the range of survival rates, and to identifyregions or countries in which survival could be improved.
- Published
- 2003
7. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study
- Author
-
De Angelis R, Sant M, Coleman, Mp, Francisci, S, Baili, P, Pierannunzio, D, Trama, A, Visser, O, Brenner, H, Ardanaz, E, Bielska Lasota, M, Engholm, G, Nennecke, A, Siesling, S, Berrino, F, Capocaccia R. Hackl, M, Zielonke, N, Oberaigner, W, Henau, K, Van Eycken, E, Dimitrova, N, Valerianova, Z, Znaor, A, Dušek, L, Zvolský, M, Storm, H, Mägi, M, Aareleid, T, Malila, N, Seppä, K, Velten, M, Belot, A, Troussard, X, Launoy, G, Guizard, A, Bouvier, A, Faivre, J, Arveux, P, Maynadié, M, Woronoff, A, Robaszkiewicz, M, Baldi, I, Monnereau, A, Tretarre, B, Bossard, N, Estève, J, Colonna, M, Molinié, F, Bara, S, Schvartz, C, Lapôtre Ledoux, B, Grosclaude, P, Meyer, M, Stabenow, R, Eberle, A, Luttmann, S, Engel, J, Schubert Fritschle, G, Kieschke, J, Batzler, W, Holleczek, B, Katalinic, A, Jónasson, J, Tryggvadóttir, L, Comber, H, Bulatko, A, Mazzoleni, G, Buzzoni, C, Giacomin, A, Mancuso, P, Sardo, A, Ferretti, S, Caldarella, A, Crocetti, E, Amati, C, Bonfarnuzzo, S, Botta, L, Foschi, R, Gatta, G, Margutti, C, Minicozzi, P, Sant, M, Tereanu, C, Dal Maso, L, Serraino, D, Caldora, M, Capocaccia, R, Carrani, E, De Angelis, R, Mallone, S, Roazzi, P, Rossi, S, Santaquilani, M, Tavilla, A, Busco, S, Pannozzo, F, Quaglia, A, Vercelli, M, Gennaro, V, Ricci, P, Bisanti, L, Randi, G, PONZ DE LEON, Maurizio, Federico, Massimo, Fusco, M, Vitale, M, Usala, M, Traina, A, Zarcone, M, Cusimano, R, Vitale, F, Michiara, M, Tumino, R, Di Felice, E, Rossi, P, Falcini, F, Iannelli, A, Budroni, M, Sechi, O, Piffer, S, Madeddu, A, Tisano, F, Fanetti, A, Tessandori, R, Rosso, S, Zanetti, R, Candela, P, Scuderi, T, Bianconi, F, La Rosa, F, Contiero, P, Tagliabue, G, Guzzinati, S, Zambon, P, Pildava, S, Smailyte, G, Agius, D, Micallef, R, Johannesen, T, Góźdź, S, Mężyk, R, Rachtan, J, Bębenek, M, Błaszczyk, J, Forjaz de Lacerda, G, Antunes, L, Bento, M, Mayer da Silva, A, Miranda, A, Coza, D, Nicula, F, Diba, C, Primic Zakelj, M, Almar, E, Mateos, A, Bidaurrazaga, J, Larrañaga, N, Torrella Ramos, A, Díaz García, J, Jimenez Chillaron, R, Izquierdo Font, A, Marcos Gragera, R, Martinez, C, Sanchez, M, Chirlaque, M, Navarro, C, Moreno Iribas, C, García, S, Peris Bonet, R, Carulla, M, Galceran, J, Khan, S, Lambe, M, Jundt, G, Bouchardy, C, Usel, M, Frick, H, Lorez, M, Ess, S, Herrmann, C, Bordoni, A, Spitale, A, Konzelmann, I, Lutz, J, Coebergh, J, Lemmens, V, Aben, K, Otter, R, Allemani, C, Coleman, M, Rachet, B, Davies, E, Easey, N, Lawrence, G, Meechan, D, Moran, T, Rashbass, J, Roche, M, Verne, J, Wilkinson, J, Bannon, F, Gavin, A, Brewster, D, Reynolds, S., Faculty of Behavioural, Management and Social Sciences, De Angelis, R, Sant, M, Coleman, M, Francisci, S, Baili, P, Pierannunzio, D, Trama, A, Visser, O, Brenner, H, Ardanaz, E, Bielska Lasota, M, Engholm, G, Nennecke, A, Siesling, S, Berrino, F, Capocaccia, R, Vitale, F., Bouchardy Magnin, Christine, and Usel, Massimo
- Subjects
Gerontology ,Adult ,Male ,Time Factors ,Adolescent ,Colorectal cancer ,Population ,Settore MED/42 - Igiene Generale E Applicata ,IR-88481 ,NO ,Prostate cancer ,Breast cancer ,METIS-300341 ,Neoplasms ,medicine ,Humans ,Lung cancer ,education ,Age Factors ,Aged ,Europe ,Female ,Middle Aged ,Retrospective Studies ,ddc:613 ,education.field_of_study ,Relative survival ,business.industry ,Oncology, cancer survival, eurocare ,Cancer ,Retrospective cohort study ,cancer survival ,age ,country ,Eurocare 5 ,medicine.disease ,Cancer survival ,Oncology ,Neoplasms/mortality ,business ,Demography - Abstract
Background: Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods: In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were applied to all datasets. For patients diagnosed 2000-07, we calculated 5-year relative survival for 46 cancers weighted by age and country. We also calculated country-specific and age-specific survival for ten common cancers, together with survival differences between time periods (for 1999-2001, 2002-04, and 2005-07). Findings: 5-year relative survival generally increased steadily over time for all European regions. The largest increases from 1999-2001 to 2005-07 were for prostate cancer (73·4% [95% CI 72·9-73·9] vs 81·7% [81·3-82·1]), non-Hodgkin lymphoma (53·8% [53·3-54·4] vs 60·4% [60·0-60·9]), and rectal cancer (52·1% [51·6-52·6] vs 57·6% [57·1-58·1]). Survival in eastern Europe was generally low and below the European mean, particularly for cancers with good or intermediate prognosis. Survival was highest for northern, central, and southern Europe. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon, and lung cancers. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation. Survival usually decreased with age, although to different degrees depending on region and cancer type. Interpretation: The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe. Likely explanations of differences in survival between countries include: differences in stage at diagnosis and accessibility to good care, different diagnostic intensity and screening approaches, and differences in cancer biology. Variations in socioeconomic, lifestyle, and general health between populations might also have a role. Further studies are needed to fully interpret these findings and how to remedy disparities. Funding: Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation, Cariplo Foundation. © 2014 Elsevier Ltd.
- Published
- 2014
8. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project
- Author
-
Stiller, C. A, Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., Ascoli, V., Zielonk, N., Van Eycken, E., Sundseth, H., Hedelin, G., Bouvier, A. M., Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Baconnier, S., Holleczek, B., Geissler, J., Wartenberg, M., Tryggvadottir, L., Deady, S., Bellu, F., Ferretti, Stefano, Vercelli, M., Vitarelli, S., Federico, M., Fusco, M., Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Tagliabue, G., Zambon, P., Gatta, G., Gronchi, A., Licitra, L., Ruzza, M., Sowe, S., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Bielska Lasota, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic Zakelj, M., Mateos, A., Bidaurrazaga, J., Torrella Ramos, A., Ardanaz, E., Galceran, J., Martinez Garcia, C., Sanchez Perez, M. J., Melchor, J. M., Adolfsson, J., Lambe, M., Möller, T. R., Ringborg, U., Jundt, G., Usel, M., Ess, S. M., Spitale, A., Konzelmann, I., Lutz, J. M., Coebergh, J. W. W., Otter, R., Siesling, S., van der Zwan, J. M., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Meechan, D., Lawrence, G., Mackay, J., Gavin, A., Kunkler, I., and White, C.
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Cancer Research ,Survival ,Epidemiology ,Population ,Socio-culturale ,Kaposi ,Bone Sarcoma ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,Prevalence ,Humans ,Rare cancers ,education ,Sarcoma, Kaposi ,ddc:613 ,Aged ,Population-based study ,education.field_of_study ,Europe ,Incidence ,Kaposi sarcoma ,Female ,Middle Aged ,Survival Analysis ,Oncology ,Medicine (all) ,Classic Kaposi Sarcoma ,Relative survival ,business.industry ,Incidence (epidemiology) ,Cancer ,Sarcoma ,medicine.disease ,Surgery ,business - Abstract
Kaposi sarcoma (KS) is a virus-related malignancy which most frequently arises in skin, though visceral sites can also be involved. Infection with Kaposi sarcoma herpes virus (KSHV or HHV-8) is required for development of KS. Nowadays, most cases worldwide occur in persons who are immunosuppressed, usually because of HIV infection or as a result of therapy to combat rejection of a transplanted organ, but classic Kaposi sarcoma is predominantly a disease of the elderly without apparent immunosuppression. We analyzed 2667 KS incident cases diagnosed during 1995-2002 and registered by 75 population-based European cancer registries contributing to the RARECARE project. Total crude and age-standardized incidence rate was 0.3 per 100,000 per year with an estimated 1642 new cases per year in the EU27 countries. Age-standardized incidence rate was 0.8 per 100,000 in Southern Europe but below 0.3 per 100,000 in all other regions. The elevated rate in southern Europe was attributable to a combination of classic Kaposi sarcoma in some Mediterranean countries and the relatively high incidence of AIDS in several countries. Five-year relative survival for 2000-2002 by the period method was 75%. More than 10,000 persons were estimated to be alive in Europe at the beginning of 2008 with a past diagnosis of KS. The aetiological link with suppressed immunity means that many people alive following diagnosis of KS suffer comorbidity from a pre-existing condition. While KS is a rare cancer, it has a relatively good prognosis and so the number of people affected by it is quite large. Thus it provides a notable example of the importance of networking in diagnosis, therapy and research for rare cancers.
- Published
- 2014
9. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project
- Author
-
Van Der Zwan, Jan Maarten, Trama, Annalisa, Otter, Renã©e, Larraã±aga, Nerea, Tavilla, Andrea, Marcos-gragera, Rafael, Dei Tos, Angelo Paolo, Baudin, Eric, Poston, Graeme, Links, Thera, Zielonke, N., Van Eycken, E., Sundseth, H., Hedelin, G., Faivre, JULIEN YVES STEPHAN, Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, Marco, Bara, S., Ganry, O., Grosclaude, P., Holleczek, B., Geissler, J., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, Silvia, Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, Angelo, Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., LA ROSA, FEDERICA IRENE, Contiero, P., Fiore, A., Gatta, G., Casali, P. G., Gronchi, A., Ruzza, Marta, Sowe, S., De Angelis, R., Dei Tos, A. P., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic-zakelj, M., Mateos, A., Martãnez, R., Torrella-ramos, A., Osca-gelis, G., Chirlaque, M. D., Moreno, C., Galceran, J., Martinez-garcia, C., Melchor, J. M., Sã¡nchez, M. J., Virizuela-echaburu, J. A., Cervantes, A., Adolfsson, J., Lambe, M., Mã¶ller, T. R., Ringborg, U., Jundt, G., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Lutz, J. M., Visser, O., Siesling, S., Coebergh, J. W. W., Greenberg, D. C., Wilkinson, Robert John Duncan, Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., White, C., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Bouchardy Magnin, Christine
- Subjects
Male ,Pediatrics ,Pathology ,Cancer Research ,MEDULLARY-THYROID CARCINOMA ,Survival ,Rare Diseases/epidemiology/mortality ,Neuroendocrine Tumors/epidemiology/mortality ,PROGNOSTIC-FACTORS ,MERKEL CELL-CARCINOMA ,Prevalence ,EPIDEMIOLOGY ,Cancer registry, Incidence, Prevalence, Survival, Neuroendocrine ,Registries ,Child ,education.field_of_study ,Relative survival ,Merkel cell carcinoma ,Incidence (epidemiology) ,Incidence ,Middle Aged ,Cancer registry ,Europe ,Neuroendocrine Tumors ,Neuroendocrine ,Oncology ,Child, Preschool ,Epidemiological Monitoring ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,UNITED-STATES ,DIAGNOSIS ,Europe/epidemiology ,NO ,PERIOD ANALYSIS ,Young Adult ,Rare Diseases ,Carcinoma ,medicine ,Rare neuroendocrine tumours ,Humans ,education ,Survival analysis ,ddc:613 ,Aged ,business.industry ,Infant, Newborn ,Cancer ,Infant ,NATURAL-HISTORY ,medicine.disease ,Survival Analysis ,STAGING-SYSTEMS ,business - Abstract
Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs).A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%).Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended. (c) 2013 Elsevier Ltd. All rights reserved.
- Published
- 2013
10. Oesophageal cancer survival in Europe: A EUROCARE-4 study
- Author
-
Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Go´ z´dz´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo
- Subjects
Stage ,Adult ,Male ,Cancer Research ,Survival ,Adolescent ,Esophageal Neoplasms ,Epidemiology ,Socio-culturale ,Subtype ,Disease ,Europe/epidemiology ,Young Adult ,Cancer ,Europe ,Oesophagus ,Trends ,Aged ,Aged, 80 and over ,Female ,Humans ,Middle Aged ,Neoplasm Staging ,Prognosis ,Registries ,Survival Rate ,Oncology ,medicine ,80 and over ,Young adult ,Stage (cooking) ,cancer survival ,Survival rate ,ddc:613 ,Relative survival ,business.industry ,Oesophageal cancer ,Cancer survival ,medicine.disease ,Esophageal Neoplasms/mortality/pathology ,business ,Demography ,Cohort study - Abstract
Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.
- Published
- 2012
11. Rare cancers are not so rare: the rare cancer burden in Europe
- Author
-
Gatta, Gemma, Van Der Zwan, Jan Maarten, Casali, Paolo G., Siesling, Sabine, Dei Tos, Angelo Paolo, Kunkler, Ian, Otter, Renã©e, Licitra, Lisa, Mallone, Sandra, Tavilla, Andrea, Trama, Annalisa, Capocaccia, Riccardo, Hackl, M., Van Eycken, E., Schrijvers, D., Sundseth, H., Geissler, Jan, Marreaud, S., Audisio, R., Mã¤gi, M., Hedelin, G., Velten, M., Launoy, G., Guizard, A. V., Bouvier, A. M., Maynadiã©, M., Mercier, M., Buemi, A., Tretarre, B., Colonna, M., Moliniã©, F., Lacour, B., Schvartz, C., Ganry, O., Grosclaude, P., Benhamou, E., Grossgoupil, M., Coquard, I. R., Droz, J. P., Baconnier, S., Holleczek, B., Wartenberg, M., Hehlmann, R., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, S., Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, A., Michiara, M., Giacomin, A., Pastore, G., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Contiero, P., Zambon, P., Berrino, F., Casali, P. G., Gatta, G., Gronchi, A., Licitra, L., Sowe, S., Trama, A., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., Dei Tos, A. P., Brandes, A. A., England, K., Langmark, F., Rachtan, J., Mezyk, R., Zwierko, M., Bielska-lasota, M., Slowinski, J., Miranda, A., Safaei Diba, Ch, Primic-zakelj, M., Mateos, A., Izarzugaza, I., Marcos-gragera, R., Sã¡nchez, M. J., Navarro, C., Ardanaz, Eva, Galceran, J., Virizuela-echaburu, J. A., Martinez-garcia, C., Melchor, J. M., Cervantes, A., Adolfsson, Jan, Lambe, M., Mã¶ller, T. R., Ringborg, Ulrik, Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Visser, O., Otter, R., Siesling, S., Van Der Zwan, J. M., Coebergh, J. W. W., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., Steward, J., Evaluative Epidemiology Unit, Fondazione IRCCS, Comprehensive Cancer Centre North East, University of Twente [Netherlands], Cancer Research UK Edinburgh Centre [Edinburgh, UK], University of Edinburgh-MRC Institute of Genetics and Molecular Medicine [Edinburgh] (IGMM), University of Edinburgh-Medical Research Council-Medical Research Council, Integraal Kankercentrum Noord, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Fondazione IRCCS Istituto Nazionale dei Tumori, Faculty of Behavioural, Management and Social Sciences, and Usel, Massimo
- Subjects
Male ,Pediatrics ,Cancer Research ,Survival ,Rare cancers ,Europe ,MESH: Registries ,0302 clinical medicine ,MESH: Aged, 80 and over ,Rare Diseases/epidemiology ,Neoplasms ,MESH: Child ,Prevalence ,Cancer registries ,MESH: Neoplasms ,Registries ,MESH: Incidence ,Child ,media_common ,Aged, 80 and over ,MESH: Aged ,0303 health sciences ,education.field_of_study ,MESH: Middle Aged ,Relative survival ,Incidence (epidemiology) ,Incidence ,MESH: Infant, Newborn ,IR-78337 ,Middle Aged ,MESH: Infant ,3. Good health ,Oncology ,MESH: Young Adult ,030220 oncology & carcinogenesis ,Child, Preschool ,MESH: Survival Analysis ,Female ,Adult ,MESH: Rare Diseases ,medicine.medical_specialty ,Adolescent ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Rare cancers, Cancer registries, Incidence, Prevalence, Survival ,Europe/epidemiology ,NO ,03 medical and health sciences ,Young Adult ,Rare Diseases ,medicine ,media_common.cataloged_instance ,Humans ,European union ,education ,Survival analysis ,MESH: Prevalence ,030304 developmental biology ,ddc:613 ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,Public health ,MESH: Child, Preschool ,Infant, Newborn ,Cancer ,Infant ,MESH: Adult ,medicine.disease ,Survival Analysis ,MESH: Male ,Cancer registry ,MESH: Europe ,business ,Neoplasms/epidemiology ,MESH: Female - Abstract
International audience; PURPOSE: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases. MATERIALS AND METHODS: RARECARE analysed population-based cancer registry (CR) data on European patients diagnosed from 1988 to 2002, with vital status information available up to 31st December 2003 (latest date for which most CRs had verified data). The mean population covered was about 162,000,000. Cancer incidence and survival rates for 1995-2002 and prevalence at 1st January 2003 were estimated. RESULTS: Based on the RARECARE definition (incidence
- Published
- 2011
12. Survival of European patients with central nervous system tumors
- Author
-
Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, Børge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Źakelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo
- Subjects
Oncology ,Ependymoma ,Adult ,Male ,medicine.medical_specialty ,Pathology ,Cancer Research ,Adolescent ,Central Nervous System Neoplasms/mortality ,Population ,survival ,NO ,Benign tumor ,Central Nervous System Neoplasms ,Young Adult ,Sex Factors ,Internal medicine ,morphology ,medicine ,80 and over ,Humans ,Registries ,Young adult ,central nervous system tumors ,Europe ,Age Factors ,Aged ,Aged, 80 and over ,Female ,Middle Aged ,Survival Rate ,education ,Survival rate ,ddc:613 ,Medulloblastoma ,education.field_of_study ,Relative survival ,business.industry ,Cancer survival ,Cancer ,central nervous system tumors, survival, morphology, Europe ,medicine.disease ,business - Abstract
We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.
- Published
- 2011
13. Survival trends in European cancer patients diagnosed from 1988 to 1999
- Author
-
Verdecchia, Arduino, Guzzinati, Stefano, Francisci, Silvia, De Angelis, Roberta, Bray, Freddie, Allemani, Claudia, Tavilla, Andrea, Santaquilani, Mariano, Sant, Milena, Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
- Subjects
Male ,Cancer Research ,Survival ,MESH : Mortality ,MESH : Age Distribution ,MESH : Aged ,Colonoscopy ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,Prostate ,Residence Characteristics ,Neoplasms ,80 and over ,MESH : Female ,MESH: Neoplasms ,030212 general & internal medicine ,MESH: Residence Characteristics ,Young adult ,cancer survival ,MESH : Sex Distribution ,Aged, 80 and over ,MESH: Aged ,MESH: Middle Aged ,medicine.diagnostic_test ,Relative survival ,Europe ,Population registries ,Time trends ,Adolescent ,Adult ,Age Distribution ,Aged ,Female ,Humans ,Middle Aged ,Mortality ,Sex Distribution ,Survival Analysis ,Young Adult ,Oncology ,MESH: Sex Distribution ,MESH : Adult ,3. Good health ,medicine.anatomical_structure ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,MESH : Residence Characteristics ,medicine.medical_specialty ,MESH : Male ,MESH : Europe ,MESH : Young Adult ,Socio-culturale ,Rectum ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,Internal medicine ,MESH : Adolescent ,medicine ,MESH : Middle Aged ,MESH : Aged, 80 and over ,Cervix ,MESH: Age Distribution ,Survival analysis ,MESH: Adolescent ,MESH: Humans ,MESH: Mortality ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,Surgery ,MESH: Europe ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
International audience; We analysed data from 49 cancer registries in 18 European countries over the period 1988-1999 to delineate time trends in cancer survival. Survival increased in Europe over the study period for all cancer sites that were considered. There were major survival increases in 5 year age-adjusted relative survival for prostate (from 58% to 79%), colon and rectum (from 48% to 54% men and women), and breast (from 74% to 83%). Improvements were also significant for stomach (from 22% to 24%), male larynx (from 62% to 64%), skin melanoma (from 78% to 83%), Hodgkin disease (from 77% to 83%), non-Hodgkin lymphoma (from 49% to 56%), leukaemias (from 37% to 42%), and for all cancers combined (from 34% to 39% in men, and from 52% to 59% in women). Survival did not change significantly for female larynx, lung, cervix or ovary. The largest increases in survival typically occurred in countries with the lowest survival, and contributed to the overall reduction of survival disparities across Europe over the study period. Differences in the extent of PSA testing and mammographic screening, and increasing use of colonoscopy and faecal blood testing together with improving cancer care are probably the major underlying reasons for the improvements in survival for cancers of prostate, breast, colon and rectum. The marked survival improvements in countries with poor survival may indicate that these countries have made efforts to adopt the new diagnostic procedures and the standardised therapeutic protocols in use in more affluent countries.
- Published
- 2009
14. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis
- Author
-
De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Cancer Research ,MESH: Quality Control ,computer.software_genre ,MESH: Epidemiologic Methods ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,Neoplasms ,Medicine ,MESH: Neoplasms ,030212 general & internal medicine ,cancer survival ,education.field_of_study ,Database ,Relative survival ,Incidence (epidemiology) ,Europe ,Population registries ,Survival analysis ,Vital statistics ,Databases as Topic ,Epidemiologic Methods ,Humans ,Quality Control ,Oncology ,MESH : Quality Control ,3. Good health ,030220 oncology & carcinogenesis ,Population ,MESH : Europe ,MEDLINE ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH : Epidemiologic Methods ,03 medical and health sciences ,education ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,medicine.disease ,MESH : Neoplasms ,Data quality ,MESH: Europe ,MESH : Databases as Topic ,business ,computer ,MESH: Databases as Topic ,International Classification of Diseases for Oncology - Abstract
International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.
- Published
- 2009
15. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary
- Author
-
Sant, Milena, Allemani, Claudia, Santaquilani, Mariano, Knijn, Arnold, Marchesi, Francesca, Capocaccia, Riccardo, Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
- Subjects
Male ,Cancer Research ,MESH : Age Distribution ,MESH : Aged ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,Neoplasms ,Epidemiology ,Medicine ,MESH : Female ,MESH: Neoplasms ,030212 general & internal medicine ,MESH : Sex Distribution ,MESH: Aged ,MESH: Middle Aged ,Relative survival ,MESH: Sex Distribution ,Population-based cancer registries ,Middle Aged ,MESH : Adult ,Cancer survival ,EUROCARE ,Adolescent ,Adult ,Age Distribution ,Aged ,Europe ,Female ,Humans ,Sex Distribution ,Survival Analysis ,Oncology ,3. Good health ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,Skin melanoma ,Stage at diagnosis ,medicine.medical_specialty ,MESH : Male ,MESH : Europe ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Age and sex ,03 medical and health sciences ,MESH : Adolescent ,MESH : Middle Aged ,MESH: Age Distribution ,Survival analysis ,MESH: Adolescent ,MESH: Humans ,business.industry ,Advanced stage ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,MESH: Europe ,MESH : Survival Analysis ,business ,MESH: Female ,Demography - Abstract
International audience; EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.
- Published
- 2009
16. The cure of cancer: a european perspective
- Author
-
Francisci, Silvia, Capocaccia, Riccardo, Grande, Enrico, Santaquilani, Mariano, Simonetti, Arianna, Allemani, Claudia, Gatta, Gemma, Sant, Milena, Zigon, Giulia, Bray, Freddie, Janssen-Heijnen, Maryska, Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
- Subjects
Male ,Cancer Research ,Colorectal cancer ,MESH : Age Distribution ,MESH : Aged ,Gastroenterology ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Prostate cancer ,0302 clinical medicine ,Breast cancer ,MESH: Aged, 80 and over ,Colon and rectum cancer ,Cure ,Lung cancer ,Relative survival ,Statistical models ,Stomach cancer ,Oncology ,Neoplasms ,MESH : Female ,MESH: Neoplasms ,030212 general & internal medicine ,cancer survival ,Aged, 80 and over ,MESH: Aged ,MESH : Prognosis ,MESH: Middle Aged ,Middle Aged ,MESH : Adult ,Prognosis ,3. Good health ,Europe ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,MESH : Male ,MESH : Europe ,MESH : Young Adult ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH: Prognosis ,03 medical and health sciences ,Young Adult ,Age Distribution ,Internal medicine ,MESH : Adolescent ,medicine ,Humans ,MESH : Middle Aged ,MESH : Aged, 80 and over ,MESH: Age Distribution ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,Survival Analysis ,MESH : Neoplasms ,MESH: Male ,Cancer registry ,MESH: Europe ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
International audience; Cancer survival analyses based on cancer registry data do not provide direct information on the main aim of cancer treatment, the cure of the patient. In fact, classic survival indicators do not distinguish between patients who are cured, and patients who will die of their disease and in whom prolongation of survival is the main objective of treatment. In this study, we applied parametric cure models to the cancer incidence and follow-up data provided by 49 EUROCARE-4 (European Cancer Registry-based study, fourth edition) cancer registries, with the aims of providing additional insights into the survival of European cancer patients diagnosed from 1988 to 1999, and of investigating between-population differences. Between-country estimates the proportion of cured patients varied from about 4-13% for lung cancer, from 9% to 30% for stomach cancer, from 25% to 49% for colon and rectum cancer, and from 55% to 73% for breast cancer. For all cancers combined, estimates varied between 21% and 47% in men, and 38% and 59% in women and were influenced by the distribution of cases by cancer site. Countries with high proportions of cured and long fatal case survival times for all cancers combined were characterised by generally favourable case mix. For the European pool of cases both the proportion of cured and the survival time of fatal cases were associated with age, and increased from the early to the latest diagnosis period. The increases over time in the proportions of Europeans estimated cured of lung, stomach and colon and rectum cancers are noteworthy and suggest genuine progress in cancer control. The proportion of cured of all cancers combined is a useful general indicator of cancer control as it reflects progress in diagnosis and treatment, as well as success in the prevention of rapidly fatal cancers.
- Published
- 2009
17. Long-term survival expectations of cancer patients in Europe in 2000-2002
- Author
-
Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Gerontology ,Male ,Cancer Research ,MESH: Registries ,Survival ,MESH : Life Expectancy ,MESH : Age Distribution ,MESH : Aged ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,Neoplasms ,80 and over ,Medicine ,Cancer registries ,MESH: Neoplasms ,MESH : Female ,030212 general & internal medicine ,Registries ,Young adult ,MESH: Aged ,Aged, 80 and over ,MESH: Middle Aged ,Relative survival ,MESH : Adult ,Middle Aged ,MESH : Survival Rate ,Prognosis ,3. Good health ,Europe ,Survival Rate ,Oncology ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,Cohort ,Period Analysis ,Female ,cancer survival - long term ,MESH: Life Expectancy ,Adult ,MESH: Survival Rate ,Period analysis ,Adolescent ,Age Distribution ,Aged ,Humans ,Life Expectancy ,Survival Analysis ,Young Adult ,MESH : Male ,MESH : Europe ,MESH : Young Adult ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,MESH : Adolescent ,MESH : Middle Aged ,MESH : Aged, 80 and over ,Survival rate ,MESH: Age Distribution ,Survival analysis ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,Life expectancy ,MESH: Europe ,MESH : Survival Analysis ,business ,MESH: Female ,MESH : Registries ,Demography - Abstract
International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.
- Published
- 2009
18. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States
- Author
-
Sant, Milena, Allemani, Claudia, De Angelis, Roberta, Carbone, Antonino, De SanJose, Silvia, Gianni, Alessandro M., Giraldo, Pilar, Marchesi, Francesca, Marcos-Gragera, Rafael, Martos-Jimenez, Carmen, Maynadie, Marc, Raphael, Martine, Berrino, Franco, Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., MacE-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estãve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Ferretti, S., Contil, E., Ramazzotti, V., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Capocaccia, R., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska-Lasota, M., Wronkowski, Z., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does-Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Mã¸ller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Steward, J. A., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Miguel Servet, Registre des hémopathies malignes de Côte d'Or, Laboratoire d'Hématologie, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospital Universitario Miguel Servet, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Oncology ,Cancer Research ,Survival ,Lymphoma ,MESH: Registries ,MESH : Age Distribution ,MESH : Aged ,MESH : Child, Preschool ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,MESH: Lymphoma, Non-Hodgkin ,MESH : Child ,MESH: Child ,hemic and lymphatic diseases ,80 and over ,Medicine ,Registries ,Child ,Aged, 80 and over ,MESH: Aged ,MESH: Middle Aged ,MESH : Prognosis ,Relative survival ,Lymphoma, Non-Hodgkin ,EUROCARE ,Non-Hodgkin's lymphoma ,Population cancer registries ,US SEER ,Adolescent ,Adult ,Age Distribution ,Aged ,Child, Preschool ,Europe ,Feasibility Studies ,Humans ,Infant ,Middle Aged ,Prognosis ,United States ,Absolute risk reduction ,MESH : Infant ,MESH : Adult ,MESH: Infant ,3. Good health ,030220 oncology & carcinogenesis ,morphology - survival - non Hodgkin lymphoma - Europe - US ,epidemiology ,medicine.medical_specialty ,MESH : United States ,MESH : Feasibility Studies ,MESH : Europe ,Socio-culturale ,Non-Hodgkin ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,survival ,MESH: Prognosis ,cancer ,03 medical and health sciences ,Internal medicine ,MESH : Adolescent ,MESH: United States ,MESH : Lymphoma, Non-Hodgkin ,MESH : Middle Aged ,Preschool ,MESH : Aged, 80 and over ,MESH: Age Distribution ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH: Child, Preschool ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,Confidence interval ,Cancer registry ,Hodgkin lymphoma ,MESH: Europe ,business ,MESH: Feasibility Studies ,MESH : Registries ,030215 immunology - Abstract
International audience; We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.
- Published
- 2008
19. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study
- Author
-
Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
MESH: Registries ,MESH : Mortality ,MESH : Aged ,Uterine Cervical Neoplasms ,Disease ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,MESH: Aged, 80 and over ,0302 clinical medicine ,MESH : Female ,Registries ,MESH: Aged ,Cervical cancer ,Aged, 80 and over ,0303 health sciences ,education.field_of_study ,MESH: Middle Aged ,MESH : Prognosis ,Relative survival ,Absolute risk reduction ,Obstetrics and Gynecology ,Middle Aged ,MESH : Adult ,Prognosis ,MESH : Survival Rate ,3. Good health ,MESH: Uterine Cervical Neoplasms ,Europe ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Female ,Adult ,medicine.medical_specialty ,MESH: Survival Rate ,Adolescent ,Population ,MESH : Uterine Cervical Neoplasms ,MESH : Europe ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH: Prognosis ,Trends - cervical cancer - survival ,03 medical and health sciences ,MESH : Adolescent ,medicine ,Humans ,MESH : Middle Aged ,Mortality ,education ,MESH : Aged, 80 and over ,Survival rate ,030304 developmental biology ,Aged ,MESH: Adolescent ,Gynecology ,MESH: Humans ,MESH: Mortality ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,Population-based study ,Survival ,Trends ,medicine.disease ,MESH: Europe ,business ,MESH: Female ,MESH : Registries ,Demography - Abstract
International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.
- Published
- 2007
20. Survival from rare cancer in adults: a population-based study
- Author
-
Gatta, G., Ciccolallo, L., Kunkler, I., Capocaccia, R., Berrino, F., Coleman, M. P., De Angelis, R., Faivre, J., Lutz, J. M., Martinez, C., Möller, T., Sankila, R., Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Chaplain, G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Crosignani, P., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníkováa, A., Pompe Kirn, V., Primic Zakelj, M., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Bouchardy, C., Coebergh, J. W. W., van der Does van den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Registre Genevois des Tumeurs, CHU Genève, Service of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Male ,Oncology ,MESH : Risk ,MESH : Aged ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,Neoplasms ,Angiosarcoma ,MESH: Neoplasms ,MESH : Female ,MESH: Quality of Health Care ,MESH: Aged ,0303 health sciences ,MESH: Risk ,MESH: Middle Aged ,Relative survival ,MESH : Quality of Health Care ,Rare cancer survival ,population-based cancer study ,international comparison ,Middle Aged ,MESH : Adult ,3. Good health ,Europe ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,MESH : Rare Diseases ,Female ,Sarcoma ,Adult ,Risk ,MESH: Rare Diseases ,medicine.medical_specialty ,Adolescent ,MESH : Male ,MESH : Europe ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,Rare Diseases ,Internal medicine ,MESH : Adolescent ,medicine ,Carcinoma ,Humans ,MESH : Middle Aged ,Testicular cancer ,Survival analysis ,Aged ,Quality of Health Care ,030304 developmental biology ,MESH: Adolescent ,MESH: Humans ,Uterine sarcoma ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,medicine.disease ,Survival Analysis ,MESH : Neoplasms ,MESH: Male ,MESH: Europe ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
International audience; BACKGROUND: Rare cancers are a challenge to clinical practice, and treatment experience, even in major cancer centres to which rare cancers are usually referred, is often limited. We aimed to study the epidemiology of rare cancers in a large population of several countries. METHODS: We analysed survival by age, sex, subsite, and morphology in 57,144 adults with 14 selected rare cancers diagnosed 1983-94. Variations in survival over time and between European regions were also assessed for variations in quality of care. We also estimated the adjusted relative excess risk of death for every rare cancer. FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]). Survival was usually better for women than men and poor in those aged 75 years or older. Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver. Survival in northern Europe was higher than in the other geographic groupings for most cancers. INTERPRETATION: Because effective treatments are available for several of the rare cancers we assessed, further research is needed to ascertain why survival is lower in some European countries than in others, particularly in older patients. Audit of best practice for rare cancers with treatment protocols would be useful.
- Published
- 2006
21. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis
- Author
-
Capocaccia, R., Gatta, G., Roazzi, P., Carrani, E., Santaquilani, M., De Angelis, R., Tavilla, A., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Faivre, J. n. Chaplain G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, J., Kaatch, P., Ziegler, H., Hölzel, D., Fritschle, G. S., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Hartley, S., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kim, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Perisbonet, R., Barlow, L., Möller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.
- Subjects
Adult ,Male ,Quality Control ,computer.software_genre ,Stomach Neoplasms ,Neoplasms ,Autopsy Only ,Cancer survival, Data quality, Population-based cancer registries ,standardisation - quality control - statistical analysis ,medicine ,Humans ,Statistical analysis ,Registries ,Medical diagnosis ,Stage (cooking) ,Child ,cancer survival ,methodology - data collection ,Data collection ,Database ,Relative survival ,business.industry ,Data Collection ,Age Factors ,Cancer ,Hematology ,medicine.disease ,Survival Analysis ,Europe ,Survival Rate ,Databases as Topic ,Oncology ,Data quality ,Female ,Colorectal Neoplasms ,business ,computer - Abstract
The EUROCARE database contains data on 6.5 million cancer patients diagnosed from 1978 to 1994 in populations covered by 67 cancer registries in 22 European countries. The quality-checked entries specify age, sex, diagnosis date, cancer site, morphology, microscopic confirmation and vital status, as well as containing broad indicators of stage. For EUROCARE-3, which refers to diagnoses from 1990 to 1994, 3389 cases with major data problems and 142,525 second or subsequent cancers were removed, leaving more than 2 million cases for analysis. From these data, observed and relative survival for each cancer site and country were calculated at 1, 3 and 5 years from diagnosis. Overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures. Overall, 1.1% of cases were lost to follow-up, 4.2% were known from death certificates only and 1.2% were known at autopsy only. The percentage of microscopically confirmed cases varied with cancer site and country, and was always higher in northern European countries. Comparison of quality indicators for the EUROCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved.
- Published
- 2003
22. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe
- Author
-
Sant, M., Allemani, C., Capocaccia, R., Hakulinen, T., Aareleid, T., Coebergh, J. W., Coleman, M. P., Grosclaude, P., Martinez, C., Bell, J., Youngson, J., Berrino, F., Kupp, A., Hedelin, G., Chaplain, G., Exbrayat, C., Tretarre, B., Mace Lesech, J., Danzon, A., Mercier, M., Raverdy, N., Artioli, E., Federico, Massimo, Barchielli, A., Paci, E., Gatta, G., Crosignani, P., Speciale, D., Ruzza, M. R., Frassoldi, E., Verdecchia, A., Gafa, L., Tumino, R., La Rosa, M., Voogd, A., and Williams, E. M. I.
- Subjects
Adult ,medicine.medical_specialty ,Cancer Research ,Population ,Breast Neoplasms ,Adenocarcinoma ,Breast cancer ,Risk Factors ,Epidemiology ,medicine ,Humans ,Registries ,Stage (cooking) ,education ,Survival rate ,Aged ,Neoplasm Staging ,education.field_of_study ,Breast cancer, Care, Europe, Population registries, Survival ,Relative survival ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Prognosis ,Surgery ,Europe ,Survival Rate ,Oncology ,Relative risk ,Female ,Lymph Nodes ,business ,Demography ,Follow-Up Studies - Abstract
We used multiple regression models to assess the influence of disease stage at diagnosis on the 5-year relative survival of 4,478 patients diagnosed with breast cancer in 1990-1992. The cases were representative samples from 17 population-based cancer registries in 6 European countries (Estonia, France, Italy, Netherlands, Spain and UK) that were combined into 9 regional groups based on similar survival. Five-year relative survival was 79% overall, varying from 98% for early, node-negative (T1N0M0) tumours; 87% for large, node-negative (T2-3N0M0) tumours; 76% for node-positive (T1-3N+M0) tumours and 55% for locally advanced (T4NxM0) tumours to 18% for metastatic (M1) tumours and 69% for tumours of unspecified stage. There was considerable variation across Europe in relative survival within each disease stage, but this was least marked for early node-negative tumours. Overall 5-year relative survival was highest in the French group of Bas-Rhin, Cote d'Or, Herault and Isere (86%), and lowest in Estonia (66%). These geographic groups were characterised by the highest and lowest percentages of women with early stage disease (T1N0M0: 39% and 9%, respectively). The French, Dutch and Italian groups had the highest percentage of operated cases. The number of axillary nodes examined, a factor influencing nodal status, was highest in Italy and Spain. After adjusting for TNM stage and the number of nodes examined, survival differences were greatly reduced, indicating that for these women, diagnosed with breast cancer in Europe during 1990-1992, the survival differences were mainly due to differences in stage at diagnosis. However, in 3 regional groups, the relative risks of death remained high even after these adjustments, suggesting less than optimal treatment. Screening for breast cancer did not seem to affect the survival patterns once stage had been taken into account.
- Published
- 2003
23. Age and stage specific prevalence estimate of cancer from population based Cancer Registry using inhomogeneous Poisson process.
- Author
-
Gras, C., Daurés, J.P., and Tretarre, B.
- Subjects
CANCER ,POISSON processes ,EPIDEMIOLOGY ,BREAST cancer ,MEDICAL research - Abstract
A multi stage model is described for estimating the age and two stage specific prevalence of cancer. The disease evolution is considered as an inhomogeneous Poisson process in the Lexis diagram. Prevalences are estimated from the basic epidemiological measures (stage specific incidences and survivals). A piecewise constant hazard model is used to estimate the transition rates constructing a finite partition of age and, where it is the case, of duration. Moreover, variance calculations are described. An application to breast cancer in the Hérault (France) population is presented. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
24. Epidemiology of rare cancers and inequalities in oncologic outcomes
- Author
-
G. Gatta, A. Trama, R. Capocaccia, Monika Hackl, Elizabeth Van Eycken, Kris Henau, Nadya Dimitrova, Mario Sekerija, Ladislav Dušek, Margit Mägi, Nea Malila, Maarit Leinonen, Michel Velten, Xavier Troussard, Veronique Bouvier, Anne-Valérie Guizard, Anne-Marie Bouvier, Patrick Arveux, Marc Maynadié, Anne-Sophie Woronoff, Michel Robaszkiewicz, Isabelle Baldi, Alain Monnereau, Brigitte Tretarre, Marc Colonna, Florence Molinié, Simona Bara, Claire Schvartz, Bénédicte Lapôtre-Ledoux, Pascale Grosclaude, Roland Stabenow, Sabine Luttmann, Alice Nennecke, Jutta Engel, Gabriele Schubert-Fritschle, Jan Heidrich, Bernd Holleczek, Jón Gunnlaugur Jónasson, Kerri Clough-Gorr, Harry Comber, Guido Mazzoleni, Adriano Giacomin, Antonella Sutera Sardo, Alessandro Barchielli, Diego Serraino, Roberta De Angelis, Sandra Mallone, Andrea Tavilla, Daniela Pierannunzio, Silvia Rossi, Mariano Santaquilani, Arnold Knijn, Fabio Pannozzo, Valerio Gennaro, Lucia Benfatto, Paolo Ricci, Mariangela Autelitano, Gianbattista Spagnoli, Mario Fusco, Mario Usala, Francesco Vitale, Maria Michiara, Rosario Tumino, Lucia Mangone, Fabio Falcini, Stefano Ferretti, Rosa Angela Filiberti, Enza Marani, Arturo Iannelli, Flavio Sensi, Silvano Piffer, Maria Gentilini, Anselmo Madeddu, Antonio Ziino, Sergio Maspero, Pina Candela, Fabrizio Stracci, Giovanna Tagliabue, Massimo Rugge, Annalisa Trama, Gemma Gatta, Laura Botta, Riccardo Capocaccia, Santa Pildava, Giedre Smailyte, Neville Calleja, Tom Børge Johannesen, Jadwiga Rachtan, Stanisław Góźdź, Jerzy Błaszczyk, Kamila Kępska, Forjaz de Lacerda, Maria José Bento, Ana Miranda, Chakameh Safaei Diba, Enrique Almar, Nerea Larrañaga, Arantza Lopez de Munain, Ana Torrella-Ramos, José María Díaz García, Rafael Marcos-Gragera, Maria Josè Sanchez, Carmen Navarro, Diego Salmeron, Conchi Moreno-Iribas, Jaume Galceran, Marià Carulla, Mohsen Mousavi, Christine Bouchardy, Silvia M. Ess, Andrea Bordoni, Isabelle Konzelmann, Jem Rashbass, Anna Gavin, David H. Brewster, Dyfed Wyn Huws, Otto Visser, Magdalena Bielska-Lasota, Maja Primic-Zakelj, Ian Kunkler, Ellen Benhamou, Gatta G., Trama A., Capocaccia R., Hackl M., Eycken E.V., Henau K., Dimitrova N., Sekerija M., Dusek L., Magi M., Malila N., Leinonen M., Velten M., Troussard X., Bouvier V., Guizard A.-V., Bouvier A.-M., Arveux P., Maynadie M., Woronoff A.-S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Stabenow R., Luttmann S., Nennecke A., Engel J., Schubert-Fritschle G., Heidrich J., Holleczek B., Jonasson J.G., Clough-Gorr K., Comber H., Mazzoleni G., Giacomin A., Sardo A.S., Barchielli A., Serraino D., De Angelis R., Mallone S., Tavilla A., Pierannunzio D., Rossi S., Santaquilani M., Knijn A., Pannozzo F., Gennaro V., Benfatto L., Ricci P., Autelitano M., Spagnoli G., Fusco M., Usala M., Vitale F., Michiara M., Tumino R., Mangone L., Falcini F., Ferretti S., Filiberti R.A., Marani E., Iannelli A., Sensi F., Piffer S., Gentilini M., Madeddu A., Ziino A., Maspero S., Candela P., Stracci F., Tagliabue G., Rugge M., Botta L., Pildava S., Smailyte G., Calleja N., Johannesen T.B., Rachtan J., Gozdz S., Blaszczyk J., Kepska K., de Lacerda F., Bento M.J., Miranda A., Diba C.S., Almar E., Larranaga N., de Munain A.L., Torrella-Ramos A., Diaz Garcia J.M., Marcos-Gragera R., Sanchez M.J., Navarro C., Salmeron D., Moreno-Iribas C., Galceran J., Carulla M., Mousavi M., Bouchardy C., Ess S.M., Bordoni A., Konzelmann I., Rashbass J., Gavin A., Brewster D.H., Huws D.W., Visser O., Bielska-Lasota M., Primic-Zakelj M., Kunkler I., and Benhamou E.
- Subjects
0301 basic medicine ,Male ,Settore MED/06 - Oncologia Medica ,0302 clinical medicine ,Neoplasms ,Epidemiology ,Prevalence ,Europe ,Population-based cancer registry ,Rare cancers ,Child ,education.field_of_study ,Relative survival ,Incidence (epidemiology) ,Incidence ,General Medicine ,Middle Aged ,Survival Rate ,Healthcare Disparitie ,Oncology ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Human ,Adult ,medicine.medical_specialty ,Adolescent ,Surgery ,Population ,Socio-culturale ,Europe, Population-based cancer registry, Rare cancers ,03 medical and health sciences ,Young Adult ,Rare Diseases ,Age Distribution ,Rare Disease ,medicine ,Humans ,Healthcare Disparities ,Sex Distribution ,education ,Survival rate ,Aged ,business.industry ,Public health ,Infant, Newborn ,Cancer ,Rare cancer ,Infant ,medicine.disease ,Clinical trial ,030104 developmental biology ,Neoplasm ,business ,Demography - Abstract
Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year survival) of all rare cancers combined and of selected rare cancers that will be in depth treated in this monographic issue. Source of the results is the RARECAREnet search tool, a database publicly available. Disparities both in incidence and survival, and consequently in prevalence of rare cancers were reported across European countries. Major differences were shown in outcome: 5-year relative survival for all rare cancers together, adjusted by age and case-mix, varied from 55% or more (Italy, Germany, Belgium and Iceland) and less than 40% (Bulgaria, Lithuania and Slovakia). Similarly, for all the analyzed rare cancers, a large survival gap was observed between the Eastern and the Nordic and Central European regions. Dramatic geographical variations were assessed for curable cancers like testicular and non epithelial ovarian cancers. Geographical difference in the annual age-adjusted incidence rates for all rare cancers together varied between >140 per 100,000 (Italy, Scotland, France, Germany, and Switzerland) and
- Published
- 2019
25. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study
- Author
-
Paolo Baili, Francesca Di Salvo, Rafael Marcos-Gragera, Sabine Siesling, Sandra Mallone, Mariano Santaquilani, Andrea Micheli, Roberto Lillini, Silvia Francisci, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Baili P., Salvo F.D., Marcos-Gragera R., Siesling S., Mallone S., Santaquilani M., Micheli A., Lillini R., Francisci S., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Pierannunzio D., Roazzi P., Rossi S., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Vilardell L., Sanchez M.J., Navarro C., Moreno-Iribas C., Ardanaz E., Galceran J., Lambe M., Khan S., Mousavi M., Bouchardy C., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Lemmens V., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., Baili, P, Di Salvo, F, Marcos Gragera, R, Siesling, S, Mallone, S, Santaquilani, M, Micheli, A, Lillini, R, Francisci, S, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
- Subjects
Cancer Research ,Population ,Population-based cancer registrie ,All cancer ,Gross domestic product ,Case-mix by cancer site ,Case mix index ,Health care ,Medicine ,education ,METIS-311842 ,education.field_of_study ,Relative survival ,business.industry ,Cancer ,Cancer survival ,Population-based cancer registries ,medicine.disease ,Eastern european ,Oncology ,EUROCARE ,business ,IR-97293 ,Demography - Abstract
Background: Overall survival after cancer is frequently used when assessing a health care service’s performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case- mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based cancer registries, using complete and period approach. Results: Denmark, United Kingdom (UK) and Eastern European countries had lower survival than neighbouring countries. Five-year ACRS has been increasing throughout Europe, and substantial increases, between 1999–2001 and 2005–2007, have been achieved in countries where survival was lower in the past. Five-year ACRS for men and women are positively correlated with macro-economic variables like the Gross Domestic Product (GDP) and Total National Expenditure on Health (TNEH) (R2 about 70%). Countries with recent larger increases in GDP and TNEH had greater increases in cancer survival. Conclusions: ACRS serves to compare all cancer survival in Europe taking account of the geographical variability in case-mixes. The EUROCARE-5 data on ACRS confirm previous EUROCARE findings. Survival appears to correlate with macro-economic determinants, particularly with investments in the health care system.
- Published
- 2015
26. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5
- Author
-
Rafael Marcos-Gragera, Sandra Mallone, Lambertus A. Kiemeney, Loreto Vilardell, Núria Malats, Yves Allory, Milena Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A. M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, K. Aben, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Marcos-Gragera R., Mallone S., Kiemeney L.A., Vilardell L., Malats N., Allory Y., Sant M., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
- Subjects
Cancer Research ,medicine.medical_specialty ,Urinary system ,Population ,Population-based cancer registrie ,Internal medicine ,Medicine ,education ,Gynecology ,education.field_of_study ,Urinary bladder ,Relative survival ,business.industry ,Urinary bladder tumours ,Cancer survival ,EUROCARE ,Kidney cancer ,Population-based cancer registries ,Cancer ,medicine.disease ,Population based study ,medicine.anatomical_structure ,Oncology ,business - Abstract
Background This work presents relative survival estimates regarding urinary tract tumours among adult patients (age ⩾ 15 years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000–2007, and on survival time trends from 1999–2001 to 2005–2007. Methods Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000–2007; the period approach was used to estimate survival over time. Results The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000–2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only. Conclusions Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
- Published
- 2015
27. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999- 2007: Results of EUROCARE-5
- Author
-
Côme Lepage, Riccardo Capocaccia, Monika Hackl, Valerie Lemmens, Esther Molina, Daniela Pierannunzio, Milena Sant, Annalisa Trama, Jean Faivre, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, L. van der Geest, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., Sant M., Trama A., Faivre J., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Ma gi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapo tre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jo nasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sutera Sardo A., Mancuso P., Ferretti S., Crocetti E., Caldarella A., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Serraino D., Dal Maso L., De Angelis R., Caldora M., Carrani E., Francisci S., Mallone S., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Staiti R., Vitale F., Ravazzolo B., Michiara M., Tumino R., Giorgi Rossi P., Di Felice E., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., C. Fanetti A., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Bianconi F., Tagliabue G., Contiero P., Dei Tos A.P., Guzzinati S., Pildava S., Smailyte G., Calleja N., Agius D., Johannesen T.B., Rachtan J., Go zdz S., Me zyk R., Baszczyk J., Bebenek M., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Ramirez C., Errezola M., Bidaurrazaga J., Torrella-Ramos A., Diaz Garcia J.M., Jimenez-Chillaron R., Marcos-Gragera R., Izquierdo Font A., Sanchez M.J., Chang D.Y.L., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., van der Geest L., Otter R., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Donnelly C., Brewster D.H., Huws D.W., and White C.
- Subjects
Cancer Research ,medicine.medical_specialty ,Survival ,Biliary tract cancer ,Cancer registry ,Europe ,Pancreatic cancer ,Primary liver cancer ,Time trends in survival ,Oncology ,Population ,Socio-culturale ,Gastroenterology ,Internal medicine ,medicine ,education ,Survival analysis ,education.field_of_study ,Relative survival ,business.industry ,Gallbladder ,Cancer ,medicine.disease ,medicine.anatomical_structure ,Liver cancer ,business - Abstract
Background The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. Methods This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers (“biliary tract cancers”), and pancreatic cancer diagnosed in 2000–2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999–2007 were also analysed using the period approach. Results The prognosis of the studied cancers was poor. Age-standardised 5-year RS was 12% for liver cancer, 17% for biliary tract cancers and 7% for pancreatic cancer. There were some between-country differences in survival. In general, RS was low in Eastern Europe and high in Central and Southern Europe. For all sites, 5-year RS was similar in men and women and decreased with advancing age. No substantial changes in survival were reported for pancreatic cancer over the period 1999–2007. On average, there was a crude increase in 5-year RS of 3 percentage points between the periods 1999–2001 and 2005–2007 for liver cancer and biliary tract cancers. Conclusions The major changes in imaging techniques over the study period for the diagnosis of the three studied cancers did not result in an improvement in the prognosis of these cancers. In the near future, new innovative treatments might be the best way to improve the prognosis in these cancers.
- Published
- 2015
28. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study
- Author
-
Annalisa Trama, Roberto Foschi, Nerea Larrañaga, Milena Sant, Rafael Fuentes-Raspall, Diego Serraino, Andrea Tavilla, Liesbet Van Eycken, Nicola Nicolai, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M. F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M. J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S. M. Ess, H. Frick, M. Lorez, S.M. Ess, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Trama A., Foschi R., Larranaga N., Sant M., Fuentes-Raspall R., Serraino D., Tavilla A., Eycken L.V., Nicolai N., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Margutti C., Meneghini E., Minicozzi P., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Mallone S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Gozdz R., Me zyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Survival ,Relative survival ,business.industry ,Cancer registrie ,Incidence (epidemiology) ,Prostate ,Cancer ,Penile cancer ,medicine.disease ,Prostate cancer ,medicine.anatomical_structure ,Internal medicine ,Cancer registries ,Penile cancers ,Survival trends ,Testicular ,Survival trend ,medicine ,business ,Penis ,Testicular cancer - Abstract
Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000–2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999–2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. Conclusions Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients’ survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.
- Published
- 2015
29. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods
- Author
-
Silvia Rossi, Paolo Baili, Riccardo Capocaccia, Massimiliano Caldora, Eugenio Carrani, Pamela Minicozzi, Daniela Pierannunzio, Mariano Santaquilani, Annalisa Trama, Claudia Allemani, Aurelien Belot, Carlotta Buzzoni, Matthias Lorez, Roberta De Angelis, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, V. Ho, S. Siesling, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Rossi S., Baili P., Capocaccia R., Caldora M., Carrani E., Minicozzi P., Pierannunzio D., Santaquilani M., Trama A., Allemani C., Belot A., Buzzoni C., Lorez M., De Angelis R., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Giacomin A., Sutera Sardo A., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Serraino D., Zucchetto A., Francisci S., Mallone S., Roazzi P., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Giorgi Rossi P., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Dei Tos A.P., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Diaz Garcia J.M., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Ho V., Siesling S., Coleman M., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., and Otter R.
- Subjects
Cancer Research ,Survival ,Population ,Socio-culturale ,Population-based registries ,Population-based registrie ,Quality checks ,Cancer ,EUROCARE ,Europe ,Oncology ,Medicine ,education ,education.field_of_study ,Relative survival ,business.industry ,Population size ,Comparability ,Percentage point ,medicine.disease ,Quality check ,Data quality ,Cohort ,business ,Demography - Abstract
Background Since 25 years the EUROCARE study monitors the survival of cancer patients in Europe through centralised collection, quality check and statistical analysis of population-based cancer registries (CRs) data. The European population covered by the study increased remarkably in the latest round. The study design and statistical methods were also changed to improve timeliness and comparability of survival estimates. To interpret the EUROCARE-5 results on adult cancer patients better here we assess the impact of these changes on data quality and on survival comparisons. Methods In EUROCARE-5 the survival differences by area were studied applying the complete cohort approach to data on nearly nine million cancer patients diagnosed in 2000–2007 and followed up to 2008. Survival time trends were analysed applying the period approach to data on about 10 million cancer cases diagnosed from 1995 to 2007 and followed up to 2008. Differently from EUROCARE-4, multiple primary cancers were included and relative survival was estimated with the Ederer II method. Results EUROCARE-5 covered a population of 232 million resident persons, corresponding to 50% of the 29 participating countries. The population coverage increased particularly in Eastern Europe. Cases identified from death certificate only (DCO) were on average 2.9%, range 0–12%. Microscopically confirmed cases amounted to over 85% in most CRs. Compared to previous methods, including multiple cancers and using the Ederer II estimator reduced survival estimates by 0.4 and 0.3 absolute percentage points, on average. Conclusions The increased population size and registration coverage of the EUROCARE-5 study ensures more robust and comparable estimates across European countries. This enlargement did not impact on data quality, which was generally satisfactory. Estimates may be slightly inflated in countries with high or null DCO proportions, especially for poor prognosis cancers. The updated methods improved the comparability of survival estimates between recently and long-term established registries and reduced biases due to informative censoring.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.